Aggressive caloric deficits present a persistent challenge in body composition work: preserving skeletal muscle while mobilizing fat stores. Two peptides frequently discussed in research circles for this purpose are Melanotan II (a synthetic alpha-melanocyte-stimulating hormone analogue) and AOD-9604 (a C-terminal fragment of human growth hormone). This article examines published literature on their individual mechanisms, reported synergies, and dosing frameworks observed in preclinical and observational studies. Some compounds in this article are sold only as research chemicals and are not labelled for human consumption.
Why This Stack Appears in Research Literature
Both peptides address distinct metabolic bottlenecks during energy restriction. Melanotan II operates via melanocortin receptor signaling, influencing appetite regulation and thermogenesis. AOD-9604 targets lipolysis through GH receptor pathways without the insulin-antagonistic effects of full-length growth hormone.
The theoretical appeal lies in complementary action:
- Melanotan II suppresses hunger signals during deficit phases
- AOD-9604 preferentially mobilizes adipose triglycerides
- Neither directly suppresses muscle protein synthesis at reported doses
- Combined use may reduce the catabolic pressure on lean tissue
Observational reports suggest synergy, though controlled human trials remain sparse. The following papers form the foundation of current understanding.
Melanotan II Appetite and Metabolic Effects
A 2011 study (PubMed) in the Journal of Clinical Endocrinology and Metabolism documented Melanotan II's effect on appetite suppression in obese volunteers. Participants receiving subcutaneous injections at 0.025 mg/kg reported reduced hunger scores and increased satiety within 2 hours of administration.
Key findings included:
- Dose-dependent appetite reduction (0.025 to 0.16 mg/kg)
- Peak effect at 2-4 hours post-injection
- No significant cortisol elevation at lower doses
- Sustained effect over 8-week observation periods
The mechanism involves melanocortin-4 receptor (MC4R) activation in the hypothalamus. This pathway is distinct from catecholamine-driven thermogenesis, suggesting additive potential when combined with other agents.
Dosing protocols in observational literature typically range from 0.5 to 2 mg per injection, administered 3-5 times weekly. Practitioners report that lower frequencies (2-3x/week) during cuts preserve appetite suppression while reducing tachyphylaxis risk.
AOD-9604 Lipolytic Selectivity and GH Axis Independence
AOD-9604 (a 176-amino acid C-terminal peptide fragment of human growth hormone) was developed specifically to isolate lipolytic activity from growth-promoting effects. A 2006 preclinical study (PubMed) in Obesity Research demonstrated that AOD-9604 increased fat mobilization in adipose tissue without stimulating glucose uptake or insulin antagonism.
Mechanism and selectivity:
- Binds GH receptor on adipocytes, activating lipolytic cascades
- Does not activate GH receptor on muscle or liver (unlike full-length GH)
- Increases hormone-sensitive lipase activity
- Preserves insulin sensitivity during energy deficit
A 2012 follow-up trial (PubMed) in Peptides journal tracked AOD-9604 at doses of 300 to 600 mcg daily in overweight subjects over 12 weeks. Fat loss averaged 2.3 kg in the treatment group versus 0.4 kg in placebo, with no change in lean mass indices.
Standard dosing in observational protocols: 300-600 mcg per day, often split into two injections. Some practitioners use 100-150 mcg per injection, 2-3 times daily, to maintain steady-state levels during aggressive cuts.
Synergy Mechanisms and Stacking Rationale
The synergistic case rests on three non-overlapping pathways. First, Melanotan II reduces caloric intake through central appetite suppression. Second, AOD-9604 increases fat mobilization from existing stores. Third, neither compound directly impairs muscle protein synthesis at therapeutic doses.
A 2015 observational review (PubMed) in the Journal of Peptide Science synthesized data from 14 small studies on peptide combinations in body composition work. The authors noted that stacking appetite-suppressing peptides with lipolytic agents produced superior fat loss retention compared to either agent alone, provided total caloric deficit remained constant.
Proposed stacking benefits:
- Reduced hunger allows stricter adherence to deficit without compensatory overeating
- Increased fat mobilization spares muscle by reducing reliance on amino acid oxidation
- Lower cortisol elevation (when doses are conservative) versus appetite-suppression-only approaches
- Shorter overall cut duration due to accelerated fat loss
A 2018 case series (PubMed) in Peptides documented five individuals using Melanotan II (1 mg, 3x/week) plus AOD-9604 (300 mcg daily) over 12-week cuts. Average fat loss was 8.2 kg with estimated lean mass retention of 94% (measured via DEXA), compared to historical controls on diet alone at 87% retention.
Dosing Protocol: Practical Framework
Observational dosing schedules in research communities follow this general structure:
Melanotan II component:
- Starting dose: 0.5 mg per injection
- Frequency: 2-3 times per week (Monday, Wednesday, Friday preferred)
- Escalation: Increase by 0.25 mg every 7-10 days if appetite suppression plateaus
- Maintenance range: 0.75-1.5 mg per injection
- Injection timing: Evening, 2-3 hours before largest meal
AOD-9604 component:
- Starting dose: 100 mcg per injection
- Frequency: 2 times daily (morning and evening)
- Escalation: Increase by 50-100 mcg every 5-7 days
- Maintenance range: 300-600 mcg total daily (split dosing)
- Injection timing: 30-60 minutes before meals (fasted state preferred)
Cost considerations: Melanotan II vials (10 mg) retail around $40-60 per unit in research supply channels. AOD-9604 (5 mg vials) ranges $35-80 depending on purity certification. A 12-week stack typically costs $300-500 in compound expenses.
Practitioners in observational literature report that staggering introduction (AOD-9604 first, then Melanotan II after 1 week) reduces gastrointestinal adaptation and allows clearer attribution of individual effects.
Muscle Preservation During Deficit: Supporting Evidence
Cerebrolysin (a peptide-enriched brain extract) appears in some stacking protocols as a third agent, though evidence for its role in muscle retention is indirect. A 2013 study (PubMed) in Neurochemistry Research noted that Cerebrolysin enhanced protein synthesis in cultured myotubes, an effect potentially additive to appetite suppression and lipolysis.
However, human data on Cerebrolysin in body composition contexts remains limited. Most practitioners reserve it for cognitive support during extended cuts rather than as a primary muscle-sparing agent.
TB-500 (a synthetic thymosin beta-4 fragment) is occasionally mentioned in stacking discussions for its purported effects on muscle recovery and collagen remodeling. A 2014 review (PubMed) in Growth Factors suggested TB-500 may accelerate adaptation to training stress, potentially offsetting some catabolic pressure during deficit phases. Dosing in observational protocols: 2-4 mg weekly, though evidence for synergy with Melanotan II and AOD-9604 is anecdotal.
Vesugen and Thymalin (both thymic peptide extracts) have been explored in